Вопросы: финаст, цинк, низорал

[FRED]

И ещё вопрос, поскольку мнения насчёт эвкапила самые разные, какие ещё доступны топические антиандрогены?

ты чё? эвкапил первый и единственный. доктор Ткачёв тут радовался как ребенок его появлению... теперь есть преп чтобы женщинам прописать.

наружные блокаторы АР это новая волна. лет через цать появится что-то... хотя мы уже знаем что именно появится.

Это ты про RU?

[vovach777]

Это ты про RU?

учёные тупые. у них всё сложно. приколись:

Future potential for therapy
The importance of the elucidation of androgenetic alopecia genes
The discovery of the genes that are involved in predisposition to androgenetic alopecia will dramatically enhance our knowledge of the mechanisms both at the molecular and cellular level that result in hair loss. For example, identifying the functional sequence change in or around the AR gene will lead to the determination of the exact differences in androgen-receptor proteins between bald and non-bald men. With this knowledge, treatments can be designed that target and reverse these differences, thereby blocking specific hair-loss mechanisms. Current pharmaceutical treatments for androgenetic alopecia do not target specific cellular mechanisms in this way. Rather, they inhibit enzymes involved in the increase of androgens in the balding scalp; thus, they are suppressive rather than curative, with variable rates of success.

The use of androgen-receptor blockers
Although the involvement of the AR gene in androgenetic alopecia is a recent finding, the idea of blocking the action of the androgen receptor in an attempt to prevent the action of excess DHT in the scalp is not new. However, androgen-receptor antagonists that act systemically cannot be used to treat men, owing to the potential risks of gynaecomastia (an excessive development of the male mammary glands), feminisation and impotence. Therefore, methods must be developed that block the action of the androgen receptor only in scalp follicles.

Knowledge of the sequence differences between the AR gene in balding and non-balding men would allow the possibility of gene-therapy techniques that could selectively deliver the non-balding AR gene to hair follicles, preventing hair loss without any systemic effects. This possibility has been advanced by the development of a topical cream containing liposomes to deliver entrapped DNA selectively to hair follicles in mice (Ref. 54). In this study, the lacZ reporter gene was successfully targeted to the hair follicles in mice after topical application of the gene entrapped in liposomes, demonstrating the feasibility in the future of the selective and safe targeting to the hair follicles of genes relevant to androgenetic alopecia. In addition, the variability in the age of onset and severity of baldness among individuals indicates that it is likely that various numbers and combinations of predisposing genes will be identified. Assuming this proves to be the case, such treatments could be designed on a case-by-case basis to target precisely those genes involved in each individual.